2015
Overview
High-dose chemotherapy refers to the administration of anticancer drugs at doses significantly higher than standard treatment protocols, typically requiring stem cell support to rescue the bone marrow from severe toxicity. Research published in the International Journal of Chemotherapy Research and Practice addresses critical aspects of this treatment approach, including the mobilization and collection of autologous peripheral blood stem cells necessary for patient recovery following intensive chemotherapy regimens. One study examined the efficacy of plerixafor as a rescue agent when initial stem cell mobilization efforts fail, a practical concern that can delay or compromise high-dose treatment plans. Additional research has explored the diagnostic challenges that arise in patients previously treated with high-dose chemotherapy for conditions such as high-risk medulloblastoma, where distinguishing between treatment-related complications, second malignancies, and disease recurrence requires sophisticated pathology techniques. This topic matters because high-dose chemotherapy remains an important treatment option for various malignancies, and optimizing supportive care measures like stem cell mobilization while accurately monitoring for long-term complications directly impacts patient outcomes and treatment success rates.
Research published in this journal
3 peer-reviewed articles, ranked by relevance. Each links to its DOI.
2015
2018
How this research is being cited
The 3 articles above have been cited 1 time in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
T. Gupta et al. · 2018 · International Journal of Neurooncology
A sample of recent works citing this journal's research on High-dose Chemotherapy, linking to each citing work.